James Wymer

Enhancing rehabilitation in people with amyotrophic lateral sclerosis

HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA)

“Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with Additional 24-Week Blinded Active Extension, to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) C302-CLN-2301

Bitner Plante Clinical Services Agreement

PLS Natural History Study Project 3

A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Antisense Oligonucleotide AMX0114 Administered to Adult Participants with Amyotrophic Lateral Sclerosis

Novel repeat associated non-AUG (RAN) proteins in sALS, sFTD and SBMA: shared pathological features and unifying therapeutic opportunities

Surveillance of Muscular Dystrophies

Multimodal longitudinal imaging of brain and cervical cord as ALS disease biomarker using microstructure statistics and morphometry

ALS/MND NATURAL HISTORY REPOSITORY SITE AGREEMENT

Clinic-based Multicenter ALS Natural History Data Collection- Supplement

Safety of Metformin in C9orf72 ALS: Effects on RAN Proteins, Breathing, Imaging, and Metabolomic Outcome Measures

PLS Natural History Project 2

Regimen-Specific Appendix (RSA) F to Master Protocol ABBV-CLS-7262

A Phase 2, randomised, double-blind, placebo-controlled, 2-way crossover study to evaluate the efficacy, safety, and tolerability of NMD670 in ambulatory adults with Type 3 spinal muscular atrophy

Regimen-Specific Appendix (RSA) F to Master Protocol ABBV-CLS-7262

Clinic-based Multicenter ALS Natural History Data Collection

Safety & therapeutic potential of metformin for C9orf72 ALS

CTOA Wymer

A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects with Amyotrophic Lateral Sclerosis (ALS)

Identifying and targeting novel repeat associated non-AUG (RAN) proteins in sporadic ALS

Novel repeat associated non-AUG (RAN) proteins in sALS, sFTD and SBMA: shared pathological features and unifying therapeutic opportunities

An Intermediate size, Expanded Access Protocol to Provide AMX0035, a Fixed Combination of Sodium Phenylbutyrate (PB) and Taurursodiol (TURSO), for the Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)

Acute adenosine receptor antagonism to promote breathing plasticity in ALS

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)